Research published in Frontiers in Psychiatry

The dynamic strategy shifting task: Optimisation of an operant task for assessing cognitive flexibility in rats.

Frontiers in Psychiatry 2024 Jonathan Martin Flintoff, Suzy Alexander, James Paul Kesby et al. 3 citations

Although schizophrenia is associated with a broad range of symptoms including hallucinations, delusions, and reduced motivation, measures of cognitive dysfunction, including cognitive flexibility and executive function, are the strongest predictors of functional outcomes. Antipsychotic medications are useful for reducing psychotic symptoms, but they are ineffective at improving cognitive...

DOI: 10.3389/fpsyt.2024.1303728 Full text Cognitive flexibility Neuropsychiatric disease Operant tasks Strategy-shifting +5

A qualitative investigation of the Montgomery-Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression.

Frontiers in Psychiatry 2024 Gianna Capodilupo, Raymond Blattner, Anita Must et al. 3 citations

Despite the development of many successful pharmaceutical interventions, a significant subset of patients experience treatment-resistant depression (TRD). Ketamine and its derivatives constitute a novel therapeutic approach to treat TRD; however, standard tools, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) are still being used to measure symptoms and track changes. The aim of...

DOI: 10.3389/fpsyt.2024.1289630 Full text Rapid acting antidepressants Rater perception Depression treatment Clinical assessment scales +3

Effectiveness of mindfulness and Qigong training for self-healing in patients with Hwabyung and depressive disorder: a protocol for a randomized controlled trial.

Frontiers in Psychiatry 2024 Seok-In Yoon, Hui-Yeong Park, Hyun Woo Lee et al. 3 citations

Hwabyung is a Korean culture-bound syndrome characterized by anger-related physical and psychological symptoms. Depressive disorder is a common mental illness occurring worldwide, and has been reported to have a high comorbidity rate with Hwabyung. For patients with depressive disorders, differential diagnosis and combined treatment for Hwabyung should be considered. Mindfulness and Qigong may...

DOI: 10.3389/fpsyt.2024.1336656 Full text Depressive disorder Mindfulness Hwabyung Qigong +1

Dissociation and recovery in psychosis - an overview of the literature.

Frontiers in Psychiatry 2024 Claudia Calciu, Rob Macpherson, Sui Yung Chen et al. 2 citations

The relationship between dissociation and recovery from psychosis is a new topic, which could attract the interest of the researchers in the field of dissociation due to its relevance to their daily clinical practice. This review brings together a diversity of international research and theoretical views on the phenomenology of dissociation, psychosis and recovery and provides a synthesis by...

DOI: 10.3389/fpsyt.2024.1327783 Full text Dissociation Psychosis Recovery Rehabilitation +1

Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System.

Frontiers in Psychiatry 2024 Tigran Makunts, Ruben Abagyan 2 citations

3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine. It is also metabolized to a lesser extent by CYP1A2, CYP2B6, and CYP3A4 to its active...

DOI: 10.3389/fpsyt.2024.1414622 Full text Molly Ddi drug-drug interaction Faers MDMA 3,4-Methylenedioxymethamphetamine +5

Corrigendum: Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

Frontiers in Psychiatry 2024 Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki et al. 1 citation correction

• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary •...

DOI: 10.3389/fpsyt.2024.1507504 Full text Esketamine Borderline personality disorder Ketamine-assisted psychotherapy kat Mental health treatment +3

The effect of a one-time mindfulness intervention on body and mind in healthy adolescents using multimodal measurements.

Frontiers in Psychiatry 2024 Angelika Ecker, Charlotte Fritsch, Daniel Schleicher et al.

Mindfulness-based interventions can improve psychological well-being and reduce symptoms of mental burden, including among adolescents. Relationships between basic mindfulness (trait mindfulness) and the immediate effects of a single mindfulness intervention have not been thoroughly researched, especially in adolescents. In this study, we aimed to elucidate these aspects by using a multimodal...

DOI: 10.3389/fpsyt.2024.1503379 Full text Adolescents Body scan Heart rate variability Mental burden +1

Addressing psychosomatic symptom distress with mindfulness-based cognitive therapy in somatic symptom disorder: mediating effects of self-compassion and alexithymia.

Frontiers in Psychiatry 2024 Lianrong Xu, Jihong Shi, Chengwen Li

This study explored the association between self-compassion, alexithymia, and psychosomatic symptom distress in a clinical sample of somatic symptom disorder (SSD) patients participating in a mindfulness-based cognitive therapy (MBCT) program. One hundred sixteen SSD patients who had participated in an MBCT program and completed ≥4 intervention sessions were included in a retrospective study...

DOI: 10.3389/fpsyt.2024.1289872 Full text Alexithymia Mindfulness-based cognitive therapy Psychosomatic distress Self-compassion +1

A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids.

Frontiers in Psychiatry 2024 David J Heal, Jane Gosden, Sharon L. Smith

Various countries and US States have legalized cannabis, and the use of the psychoactive1 and non-psychoactive cannabinoids is steadily increasing. In this review, we have collated evidence from published non-clinical and clinical sources to evaluate the abuse, dependence and associated safety risks of the individual cannabinoids present in cannabis. As context, we also evaluated various...

DOI: 10.3389/fpsyt.2024.1322434 Full text Cannabis Dependence THC - Tetrahydrocannabinol Abuse +2

Cost-effectiveness analysis of mindfulness-based cognitive therapy in patients with anxiety disorders in secondary mental health care settings alongside a randomized controlled trial.

Frontiers in Psychiatry 2024 Mitsuhiro Sado, Akihiro Koreki, Akira Ninomiya et al.

Anxiety disorder is one of the most prevalent mental disorders. Mindfulness-based cognitive therapy (MBCT) is effective for treating anxiety disorders. However, no studies have investigated the cost-effectiveness of MBCT for anxiety disorders. We aimed to conduct a cost-effectiveness analysis alongside a randomized controlled trial (RCT) to clarify the cost-effectiveness of MBCT for anxiety...

DOI: 10.3389/fpsyt.2024.1391786 Full text Anxiety disorders Cost-effectiveness Mindfulness-based cognitive therapy Randomized controlled trial

Exploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.

Frontiers in Psychiatry 2024 Xinyi Liang, Maria-Mihaela Avram, Toni Gibbs-Dean et al.

Cannabis users present an important group for investigating putative mechanisms underlying psychosis, as cannabis-use is associated with an increased risk of psychosis. Recent work suggests that alterations in belief-updating under uncertainty underlie psychosis. We therefore compared belief updating under uncertainty between cannabis and non-cannabis users. 49 regular cannabis users and 52...

DOI: 10.3389/fpsyt.2024.1309868 Full text Cannabis Belief-updating Learning Online assessment +1

Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment

Frontiers in Psychiatry December 19, 2023 Jonathan David, José Carlos Bouso, Maja Kohek et al. 14 citations

Introduction Despite an emerging understanding regarding the pivotal mechanistic role of subjective experiences that unfold during acute psychedelic states, very little has been done in the direction of better characterizing such experiences and determining their long-term impact. The present paper utilizes two cross-sectional studies for spotlighting – for the first time in the literature –...

DOI: 10.3389/fpsyt.2023.1287961 Ayahuasca Psychedelics entheogens Hallucinogens Plant medicine +8

Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management

Frontiers in Psychiatry December 8, 2023 Alina Wilkowska, Wiesław Jerzy Cubała 10 citations

Bipolar depression constitutes a major problem in psychiatry. It correlates with high suicidality, treatment resistance, chronicity, and poor quality of life. Registered treatment for bipolar depression is limited and insufficient. There is an urgent need for implementing new therapeutic strategies. Intranasal ketamine’s enantiomer—esketamine is a novel rapid-acting antidepressant with proven...

DOI: 10.3389/fpsyt.2023.1322752 Full text Esketamine Arketamine Bipolar depression Short-term treatment

Group psychedelic therapy: empirical estimates of cost-savings and improved access

Frontiers in Psychiatry December 6, 2023 Elliot Marseille, Manish Agrawal, Paul Thambi et al. 40 citations

Objective To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access. Methods Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician...

DOI: 10.3389/fpsyt.2023.1293243 MDMA Psilocybin Major depressive disorder Group psychotherapy +1

Overcoming the myths of esketamine administration: different and not difficult

Frontiers in Psychiatry November 23, 2023 Florian Buchmayer, Siegfried Kasper 19 citations

Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact on many humans lives worldwide and more than a third of treated people are not responding after several treatment attempts. Additional...

DOI: 10.3389/fpsyt.2023.1279657

5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

Frontiers in Psychiatry November 23, 2023 Anya Ragnhildstveit, Ryan Khan, Paul Seli et al. 17 citations

Psychedelic therapy is, arguably, the next frontier in psychiatry. It offers a radical alternative to longstanding, mainstays of treatment, while exciting a paradigm shift in translational science and drug discovery. There is particular interest in 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT)—a serotonergic psychedelic—as a novel, fast-acting therapeutic. Yet, few studies have directly...

DOI: 10.3389/fpsyt.2023.1271152 Adverse effect Psychopathology Clinical psychology

Biological studies of clavine alkaloids targeting CNS receptors

Frontiers in Psychiatry November 21, 2023 Peter Wipf, Nikhil R. Tasker, Ethan J. Pazur 7 citations

In contrast to well established psychedelics such as lysergic acid diethylamide (LSD) and psilocybin, ergot alkaloids of the clavine subclass have not been thoroughly investigated, in spite of their broad occurrence in nature and their well-established potent physiological effects. This study presents the current knowledge on the biological properties of clavine alkaloids, draws comparisons to...

DOI: 10.3389/fpsyt.2023.1286941 Psilocybin Lysergic acid diethylamide Hallucinogen Pharmacology +1

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample

Frontiers in Psychiatry November 13, 2023 Tor-Morten Kvam, Malin V. Uthaug, Kristoffer A A Andersen et al. 21 citations

Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of mental disorders and substance use disorders. However, knowledge about the epidemiology of classic psychedelics in the Nordic countries is limited. Methods We recruited adult, Norwegian participants who have had...

DOI: 10.3389/fpsyt.2023.1287196 Psilocybin LSD Addiction N,N-Dimethyltryptamine DMT +6

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry October 31, 2023 Albino J Oliveira-Maia, Benoit Rive, Joachim Morrens et al. 6 citations

BackgroundThe efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI). How esketamine NS compares with commonly used real-world (RW) polypharmacy...

DOI: 10.3389/fpsyt.2023.1250987 Full text Esketamine nasal spray Treatment resistant depression Real-world evidence Indirect comparison +2

A brain imaging study of dopamine receptor D2 availability in cannabis dependent users after recovery from cannabis-induced psychosis

Frontiers in Psychiatry October 27, 2023 Aviv Weinstein 3 citations

There is increased risk of psychosis associated with cannabis use disorder and the interaction of THC with dopamine neurotransmission is complex. It is important to investigate the recovery from cannabis-induced psychosis and its effects on the brain’s dopamine neurotransmission. This study was to evaluate dopamine receptor D 2 availability in the striatum (caudate/putamen) in recently...

DOI: 10.3389/fpsyt.2023.1230760 Ecstasy MDMA Cannabidiol Psychosis +3

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges

Frontiers in Psychiatry October 19, 2023 Brian S. Barnett, Anahita Bassir Nia, Nathan Sackett et al. 1 citation

Disclosures of Financial or Other Potential Conflicts of Interest: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from...

DOI: 10.3389/fpsyt.2023.1305478

Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study

Frontiers in Psychiatry October 16, 2023 Eline Haijen, Petra P M Hurks, Kim P. C. Kuypers 6 citations

Background Microdosing (MD), repeatedly taking psychedelics in small, non-hallucinogenic amounts, has been practiced by individuals to relieve attention deficit hyperactivity disorder (ADHD) symptoms. Generally, adults diagnosed with ADHD have lower levels of mindfulness and differ in personality structure from non-ADHD adults. How MD affects mindfulness and personality in adults with ADHD...

DOI: 10.3389/fpsyt.2023.1233585 Mindfulness Personality Conscientiousness Clinical psychology +4

Hippocampal subfield volumes in treatment resistant depression and serial ketamine treatment

Frontiers in Psychiatry October 9, 2023 Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, S. Joshi et al. 6 citations

Introduction Subanesthetic ketamine is a rapidly acting antidepressant that has also been found to improve neurocognitive performance in adult patients with treatment resistant depression (TRD). Provisional evidence suggests that ketamine may induce change in hippocampal volume and that larger pre-treatment volumes might be related to positive clinical outcomes. Here, we examine the effects of...

DOI: 10.3389/fpsyt.2023.1227879 Full text

Manic episode following psilocybin use in a man with bipolar II disorder: a case report

Frontiers in Psychiatry September 22, 2023 Haniya J Halim, Bradley G. Burk, Rachel E. Fargason et al. 13 citations

There has been an increase in research on the topic of psychedelic substances and their effects as treatment options in neuropsychiatric conditions. Psilocybin is a psychedelic drug that has recently garnered increased interest as an effective treatment modality for treatment-resistant depression, depression associated with terminal conditions, certain substance use disorders, and...

DOI: 10.3389/fpsyt.2023.1221131 Magic mushrooms Psilocybin Bipolar disorder Substance-induced mania +6

Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the “high-risk” addiction patient

Frontiers in Psychiatry September 20, 2023 Taylor Black 2 citations

Psychedelic-assisted treatment (PAT) for mental health is in renaissance. Psilocybin and MDMA stand near FDA approval, and US cities and states are decriminalizing or regulating the non-clinical use of psilocybin. However, neither FDA indications nor a regulated use model sufficiently address the complex needs and opportunities for an improved treatment of addiction. When paired with disability...

DOI: 10.3389/fpsyt.2023.1159843 Addiction Population Mental illness Legalization +6

Papers